The investigators analyzed collection data of 10 years for the efficacy of metformin on body mass, menstrual frequencies, metabolic and hormonal outcomes in women with polycystic ovary syndrome (PCOS) and BMI ≥ 25kg/m2. Each patient's age and height were recorded at baseline. In addition each patient weight, waist circumference, menstrual regularity, fasting glucose, glucose after 120 minute oral glucose tolerance test, luteinizing hormone, follicle stimulating hormone , free and direct testosterone, androstenedione, sex hormone binding globulin, dehydroepiandrosterone sulfate were identified at baseline and at the every follow up visit where available.
Study Type
OBSERVATIONAL
Enrollment
180
University Medical Center Ljubljana
Ljubljana, Slovenia
body weight
Primary outcome was change in body weight.
Time frame: The measurement is assessed in kilograms at the beginning and after every year of taking metformin for 10 years.
menstrual frequency
Primary outcome was change in menstrual frequency.
Time frame: The measurement is assessed in number of bleeds per year at the beginning and after every year of taking metformin for 10 years.
free testosterone
Primary outcome was change in levels of free testosterone.
Time frame: The measurement is assessed in nmol/L at the beginning and after every year of taking metformin for 10 years.
diabetes mellitus
Primary outcome was development of diabetes mellitus.
Time frame: The measurement of glucose in blood is assessed in mmol/L at the beginning and after every year of taking metformin for 10 years.
This platform is for informational purposes only and does not constitute medical advice. Always consult a qualified healthcare professional.